Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial

Gwénaël Ferron, Gaëtan De Rauglaudre,Stéphanie Becourt,Nicolas Delanoy,Florence Joly,Alain Lortholary,Benoît You,Patrick Bouchaert,Emmanuelle Malaurie,Sebastien Gouy,Marie-Christine Kaminsky,Jérôme Meunier,Jérôme Alexandre,Dominique Berton,Nadine Dohollou,Coraline Dubot,Anne Floquet,Laure Favier, Laurence Venat-Bouvet,Michel Fabbro

Gynecologic Oncology（2023）

引用 2|浏览59

暂无评分

摘要

•CHIVA assessed nintedanib integrated into a neoadjuvant strategy for ovarian cancer.•Nintedanib was associated with worse progression-free survival (primary endpoint).•Nintedanib was associated with an increase in typical chemotherapy adverse effects but not surgical complications.•Nintedanib is not recommended as part of neoadjuvant therapy for ovarian cancer.

查看译文

关键词

Anti-angiogenic,Interval debulking surgery,Neoadjuvant,Nintedanib,Ovarian cancer

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要